ASXL1 and acute myeloid leukemia: However, posttransplant OS did not differ significantly across initial treatment groups (HMA + VEN vs. IC vs. HMA + HAG/IAG; p = 0.903, Figure S2), which indicated induction regimen did not independently influence post‐HSCT survival in ASXL1‐mutated AML.